-
Tuesday's Stocks to Watch and Trading Ideas
Monday, May 2, 2011 - 5:35pm | 2446( click to enlarge ) Downward bias in Valeant Pharmaceuticals Int (NYSE:VRX). The stock broke support of $51.15 today on above average volume. Short term momentum indicators, like MACD, RSI and Stochastics are also in Bearish areas. A decline to its 50-day moving average currently at $46.13...
-
U.S. Government Expands BioThrax Procurement Contract to 17.92M Doses from 14.5M Increasing Contract Value by up to $101 Million (EBS)
Monday, May 2, 2011 - 4:42pm | 128Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has signed a modification to its current procurement contract with the U.S. government to supply an additional 3.42 million doses of BioThrax^® (Anthrax Vaccine Adsorbed). BioThrax is the only vaccine licensed by the U.S. Food and Drug...
-
United Therapeutics Files $50M Stock Securities Shelf -Bloomberg (UTHR)
Monday, May 2, 2011 - 4:41pm | 20Bloomberg reports that United Therapeutics (NASDAQ: UTHR) files $50M stock securities shelf.
-
Benzinga's Volume Movers (VLCM, CEPH, TLCR, HRBN)
Monday, May 2, 2011 - 10:47am | 160Volcom Inc (NASDAQ: VLCM) shares moved up 23.72% to $24.41 at 10:45 am. The volume of VLCM shares traded was 7274% higher than normal. PPR agreed to purchase Volcom for $607.5 million. Cephalon Inc (NASDAQ: CEPH) shares rose 5.00% to $80.87. The volume of CEPH shares traded was 1099% higher than...
-
Immunomedics Announces Results From Single-Dose Escalation Study of Y-90-Clivatuzumab Tetraxetan in Advanced Pancreatic Cancer Published
Monday, May 2, 2011 - 10:29am | 119Immunomedics, Inc. (Nasdaq: IMMU) today announced that a single dose of clivatuzumab tetraxetan labeled with the potent therapeutic radioisotope, yttrium-90, produced transient partial responses in some patients with advanced pancreatic cancer and the treatment was well tolerated with manageable...
-
J.P. Morgan Maintains Neutral Rating On SGEN
Monday, May 2, 2011 - 9:57am | 192This morning, Seattle Genetics Inc. (NASDAQ: SGEN) announced that the FDA has accepted two Biologics License Application (BLA) filings for SGN-35/B, J.P. Morgan reports. “Vedotin (BV) as a treatment for relapse/refractory Hodgkin lymphoma and anaplastic large cell lymphoma (ALCL),” J.P. Morgan...
-
PharmAthene Completes Closing Arguments and Provides Update on Litigation With SIGA Technologies
Monday, May 2, 2011 - 9:48am | 96PharmAthene, Inc. (NYSE: PIP) announced today that closing arguments in its breach of contract action against SIGA Technologies were held on Friday, April 29, 2011 in the Delaware Court of Chancery. Post trial briefs in the case were submitted by both parties to the Court in April 2011. Eric I....
-
News Summary
Monday, May 2, 2011 - 9:44am | 225Shares of Tenet Healthcare Corp (NYSE: THC) fell about 4.4% after Community Health Systems Inc (NYSE: CYH) raised its all-cash offer to acquire all outstanding shares of common stock of THC to $7.25 per share from $6 per share. Shares of Loews Corp (NYSE: L) dropped about 3.2% after the company...
-
CEOWORLD Top 10 Large Cap Stocks in April: ERIC, VMW, FMS, BBBY, WYNN, KKR, BIIB, LTD, CHU, ZNH
Monday, May 2, 2011 - 9:34am | 1246China Unicom (Hong Kong) Limited (ADR) (NYSE:CHU)- Technical indicators for the stock are Bullish and S&P gives CHU a weak 2 STARS (out of 5) sell rating. For a hedged play on this stock, look at the Oct '11 $20.00 covered call for a net debit in the $18.36 area. That is also the break-even...
-
Teva Expects $1B After Closing, $500M of Cost Savings from Purchase (CEPH. TEVA)
Monday, May 2, 2011 - 9:00am | 78Teva (NASDAQ: TEVA) says, "Cephalon (NASDAQ: CEPH) enterprise value includes conversion of convertibles... Cephalon is `great strategic fit'... sees $500M of cost savings from Cephalon purchase... sees cost savings in third year after closing... expects to have $1 billion in cash after closing......
-
UPDATE: Seattle Genetics Trading Higher Pre-Market After FDA News (SGEN)
Monday, May 2, 2011 - 8:59am | 19UPDATE: Seattle Genetics (NASDAQ: SGEN) Trading Higher Pre-Market After FDA News
-
CEOWORLD TOP 5 higher priced Biotechnology stocks picks- BIIB, CBST, MYGN, REGN and ITMN
Monday, May 2, 2011 - 8:56am | 1144Biogen Idec (NASDAQ: BIIB) announced that a newly-developed MS drug known as BG-12 has shown to be even more effective in clinical studies than Copaxone. If all goes according to plan, BG-12 will hit the market in late 2012 or the first half of 2013. Biogen Idec Inc. (Biogen Idec) is a global...
-
Rosetta Genomic Announces Research Demonstrates Power of miRview mets to Identify Tissue of Origin in Carcinoma of Unknown Primary
Monday, May 2, 2011 - 8:44am | 80Rosetta Genomics, Ltd. (NASDAQ: ROSG) announces that results of a joint study with researchers at the University of Texas, M. D. Anderson Cancer Center show that Rosetta Genomics' miRview™ mets is a powerful tool to identify Tissue of Origin in Carcinoma of Unknown Primary patients. The study,...
-
CEOWORLD Top Stocks Picks to Watch 5/2/11- DANG, HDY, KOG, TIV, SSN, MCP, PZG, AIG, SIRI, DRYS, RIMM, AMZN, CSCO…
Monday, May 2, 2011 - 8:41am | 2012E-Commerce China Dangdang Inc. (DANG) - E Commerce China Dangdang Inc is the 1st fastest-growing stock in this segment of the market. Its long-term annual EPS growth is expected to be 70.3%. This number is based on the average estimate of 3 brokerage analysts. Hyperdynamics Corporation (HDY) -...
-
Jefferies Maintains Rating, PT On CELG
Monday, May 2, 2011 - 8:31am | 111Jefferies is maintaining its Buy rating and its $68 price target on Celgene Corp. (NASDAQ: CELG) in advance of a full update of its IFM study, to be released this Thursday. Says Jefferies, in its report, “We believe the updated count of second primary malignancies (SPMs) in the French IFM study of...